These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16603829)

  • 21. Diabetic dyslipidemia or 'diabetes lipidus'?
    Muačević-Katanec D; Reiner Z
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):341-8. PubMed ID: 21438813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.
    Costa J; Borges M; David C; Vaz Carneiro A
    BMJ; 2006 May; 332(7550):1115-24. PubMed ID: 16585050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care.
    Teoh H; Després JP; Dufour R; Fitchett DH; Goldin L; Goodman SG; Harris SB; Langer A; Lau DC; Lonn EM; Mancini GB; McFarlane PA; Poirier P; Rabasa-Lhoret R; Tan MK; Leiter LA
    Diabetes Obes Metab; 2013 Dec; 15(12):1093-100. PubMed ID: 23683111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A
    Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dyslipidemia in type 2 diabetes mellitus.
    Mooradian AD
    Nat Clin Pract Endocrinol Metab; 2009 Mar; 5(3):150-9. PubMed ID: 19229235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.
    Khavandi M; Duarte F; Ginsberg HN; Reyes-Soffer G
    Curr Cardiol Rep; 2017 Jan; 19(1):7. PubMed ID: 28132397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of diet-induced dyslipidemia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes.
    Sachidanandam K; Hutchinson JR; Elgebaly MM; Mezzetti EM; Wang MH; Ergul A
    J Pharmacol Exp Ther; 2009 Jan; 328(1):123-30. PubMed ID: 18941121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triglycerides: how much credit do they deserve?
    Kohli P; Cannon CP
    Med Clin North Am; 2012 Jan; 96(1):39-55. PubMed ID: 22391250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel strategies for managing dyslipidemia: treatment beyond statins.
    Ling H; Burns TL; Hilleman DE
    Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Consensus document on the treatment of dyslipidemia in diabetes].
    Hormigo-Pozo A; Mancera-Romero J; Perez-Unanua MP; Alonso-Fernandez M; Lopez-Simarro F; Mediavilla-Bravo JJ;
    Semergen; 2015 Mar; 41(2):89-98. PubMed ID: 25533449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets.
    Ng DS
    Can J Diabetes; 2013 Oct; 37(5):319-26. PubMed ID: 24500559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Future perspectives of the pharmacological management of diabetic dyslipidemia.
    Patti AM; Giglio RV; Papanas N; Rizzo M; Rizvi AA
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):129-143. PubMed ID: 30644763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study on the glycemic, lipid and blood pressure control of type 2 diabetes patients of Kerala.
    P SK; A M S
    Diabetes Metab Syndr; 2017; 11(4):231-235. PubMed ID: 27509820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins for diabetic cardiovascular complications.
    Ludwig S; Shen GX
    Curr Vasc Pharmacol; 2006 Jul; 4(3):245-51. PubMed ID: 16842142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
    Anabtawi A; Moriarty PM; Miles JM
    Curr Cardiol Rep; 2017 Jul; 19(7):62. PubMed ID: 28528456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
    Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
    Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of dyslipidemia in patients with diabetes mellitus.
    Pikto-Pietkiewicz W; Wołkowska K; Pasierski T
    Pharmacol Rep; 2005; 57 Suppl():10-9. PubMed ID: 16415483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid Management in Diabetes with a Focus on Emerging Therapies.
    Hoe E; Hegele RA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S183-90. PubMed ID: 26653256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.